Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development
Authors:
- 3 December 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (1) , 213-225
Abstract
Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-γ were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.Keywords
Funding Information
- National Cancer Institute (R01CA138264, U01CA212007)
- Boehringer Ingelheim
This publication has 46 references indexed in Scilit:
- Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyJournal for ImmunoTherapy of Cancer, 2015
- Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID miceOncology Letters, 2014
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?The Journal of Immunology, 2013
- Compartment Model Predicts VEGF Secretion and Investigates the Effects of VEGF Trap in Tumor-Bearing MiceFrontiers in Oncology, 2013
- Human T cells depend on functional calcineurin, tumour necrosis factor-α and CD80/CD86 for expansion and activation in miceClinical and Experimental Immunology, 2012
- Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathwayImmunobiology, 2012
- Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsJournal of Pharmacokinetics and Pharmacodynamics, 2010
- Creation of “Humanized” Mice to Study Human ImmunityCurrent Protocols in Immunology, 2008
- Abnormal Lymphoid Organ Development in Immunodeficient Mutant MiceVeterinary Pathology, 2006